GlassScriptPhysician profile
Karl L Krohn
NPI 1194798686
$2,796.90
in general payments reported to CMS, 2019-2025
24 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $687 · 2020: $400 · 2021: $481 · 2022: $362 · 2023: $381 · 2024: $355 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $866.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $916.94 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $487.20 | 2019-2024 | Breztri, Farxiga |
| Pfizer INC. | $216.02 | 2020-2023 | |
| Astellas Pharma US INC | $143.65 | 2019 | |
| Lilly USA, LLC | $99.29 | 2020-2022 | |
| Paratek Pharmaceuticals, INC. | $90.35 | 2021-2023 | Nuzyra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.24 | 2019 | |
| Sanofi-Aventis U.S. LLC | $78.33 | 2019-2024 | |
| Intuitive Surgical, INC. | $74.60 | 2019 | |
| Amgen INC. | $69.24 | 2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.82 | 2023 | Jardiance |
| Abbvie INC. | $61.90 | 2022-2023 | |
| Inspire Medical Systems, INC. | $57.89 | 2025 | Inspire |
| Corcept Therapeutics | $55.04 | 2024 | Korlym |
| Exact Sciences Corporation | $54.52 | 2024-2025 | Cologuard Collection Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $50.00 | 2024 | Abre |
| Novartis Pharmaceuticals Corporation | $39.13 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $26.76 | 2023 | Rebyota |
| Janssen Pharmaceuticals, INC | $26.42 | 2021 | |
| Glaxosmithkline, LLC. | $24.32 | 2025 | Shingrix |
| Merck Sharp & Dohme LLC | $24.01 | 2021 | |
| Shire North American Group INC | $22.95 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $20.25 | 2021 | |
| Globus Medical, INC. | $16.03 | 2025 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karl Krohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.